Diuretic peptide conjugates
Disclosed are a variety of peptide conjugates represented by the following general formula: R 1 -Z-X-Z′-R 2 including methods of making and using such conjugates. Also provided are antibodies that specifically bind the peptide conjugates. The present invention has a wide spectrum of important applications including use in the treatment of disorders impacted by nociceptin and related opioid-like peptides.
1. A peptide conjugate of formula III
R 1 -X-Z′-R 2 (SEQ ID NO: 81) (III)
wherein X represents
(RK)YY(RK)(WI)(RK) (II)
wherein alternative amino acid residues at positions 1, 4, 5, and 6 are shown in brackets;
Z′ is selected from the group consisting of K 8 (SEQ ID NO:73), K 7 (SEQ ID NO:74), K 6 (SEQ ID NO:75), K 5 (SEQ ID NO:76), and K 4 (SEQ ID NO:77) wherein the amino acid residues have the D or L configuration;
R 1 represents H or an acyl group;
R 2 represents NR 3 R 4 where each of R 3 and R 4 independently represents hydrogen, C(1-6)alkoxy, aryloxy, or a lower alkyl; or R 2 represents OH; or
a salt, hydrate, or solvate thereof, or an all-D form, a retro form, or a retro all-D form thereof.
2. The peptide conjugate of claim 1 , wherein the amino acid residues in Z′ have the L-configuration.
3. The peptide conjugate of claim 1 , wherein R 1 is acetyl or trifluoroacetyl.
4. The peptide conjugate of claim 1 , wherein R 2 is NH 2 or NR 3 R 4 , wherein each of R 3 and R 4 independently is hydrogen, methyl, or ethyl.
5. The peptide conjugate of claim 1 , wherein said hexapeptide X is selected from the group consisting of KYYRWK (SEQ ID NO: 11), RYYRWR (SEQ ID NO: 3), RYYRWK (SEQ ID NO: 1), RYYRWK (SEQ ID NO: 1) (all-D), RYYRIK (SEQ ID NO: 5), RYYRIR (SEQ ID NO: 6), RYYKIK (SEQ ID NO: 7), RYYKIR (SEQ ID NO: 8), RYYKWR (SEQ ID NO: 9), and RYYKWK (SEQ ID NO: 10).
6. The peptide conjugate of claim 1 further comprising a terminal cysteinyl residue.
7. A peptide conjugate selected from the group consisting of:
Compound 8 Ac-RYYRWKKKKKKK-NH 2 (SEQ ID NO: 35) (all D),
Compound 9 Ac-KYYRWKKKKKKK-NH 2 (SEQ ID NO: 53), and
Compound 10 Ac-RYYRIKKKKKKK-NH 2 (SEQ ID NO: 41);
a C-terminal free acid thereof, an esterified derivative thereof, or a pharmaceutically acceptable acid addition salt thereof.
8. A peptide conjugate X-Z′ selected from the group consisting of KYYRWKK 6 (SEQ ID NO: 53), RYYRWKK 6 (SEQ ID NO: 35), RYYRWRK 6 (SEQ ID NO: 38), RYYRIKK 6 (SEQ ID NO: 41), and RYYRWK 5 (SEQ ID NO: 83), a pharmaceutically acceptable salt thereof or a derivative thereof wherein said derivative is an N-terminally acetylated, C-terminally amidated, or esterified derivative.
9. A pharmaceutically acceptable acid addition salt of the peptide conjugate of claim 8 selected from the group consisting of Compound 1A (Ac-RYYRWKKKKKKK-NH 2 (SEQ ID NO: 35)×9CH 3 COOH) and Compound 1C (Ac-RYYRWKKKKKKK-NH 2 (SEQ ID NO: 35)×9HCl)
10. A biologically active substance comprising a positively charged peptide conjugate of claim 1 and a pharmaceutically acceptable anion.
11. The biologically active substance of claim 10 , wherein said pharmaceutically acceptable anion is CH 3 COO − , CF 3 COO − , CF 3 COO − , Cl − , SO 3 2− maleate, or oleate.
12. A pharmaceutical composition comprising a peptide conjugate of claim 1 or an active substance of claim 10 , and a pharmaceutically acceptable carrier or diluent.
13. The pharmaceutical composition of claim 12 , further comprising a liquid carrier selected from the group consisting of syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene, and water, wherein said composition is suitable for parenteral administration.
14. The pharmaceutical composition of claim 13 , wherein said composition is in a unit dosage, wherein said unit dosage comprises an amount of said peptide conjugate ranging from about 0.1 mg to about 10 mg.
15. The peptide conjugate of claim 5 , wherein said hexapeptide X is RYYRWR (SEQ ID NO: 3).
16. The peptide conjugate of claim 1 , wherein said Z′ is K 6 (SEQ ID NO: 75).
17. The peptide conjugate of claim 8 , wherein the peptide conjugate is RYYRWRK 6 (SEQ ID NO:38).
18. The peptide conjugate of claim 8 , wherein the peptide conjugate is a derivative, wherein said derivative is an N-terminally acetylated, C-terminally amidated, or esterified derivative.
19. The derivative of claim 18 , wherein the derivative is N-terminally acetylated and C-terminally amidated.
20. The derivative of claim 19 , wherein the derivative is Ac-RYYRWRK 6 -NH 2 (SEQ ID NO:38), wherein Ac is an acetyl group and NH 2 is an amide.
21. The biologically active substance of claim 11 , wherein said pharmaceutically acceptable anion is CH 3 COO − .
22. The pharmaceutical composition of claim 13 , wherein said liquid carrier is water.
23. The peptide conjugate of claim 5 , wherein said hexapeptide X is KYYRWK (SEQ ID NO:11).
24. The peptide conjugate of claim 5 , wherein said hexapeptide X is RYYRWK (SEQ ID NO:1).
25. The peptide conjugate of claim 5 , wherein said hexapeptide X is RYYRWK (SEQ ID NO:1) (all-D).
26. The peptide conjugate of claim 5 , wherein said hexapeptide X is RYYRIK (SEQ ID NO:5).
27. The peptide conjugate of claim 5 , wherein said hexapeptide X is RYYRIR (SEQ ID NO:6).
28. The peptide conjugate of claim 5 , wherein said hexapeptide X is RYYKIK (SEQ ID NO:7).
29. The peptide conjugate of claim 5 , wherein said hexapeptide X is RYYKIR (SEQ ID NO:8).
30. The peptide conjugate of claim 5 , wherein said hexapeptide X is RYYKWR (SEQ ID NO:9)
31. The peptide conjugate of claim 5 , wherein said hexapeptide X is RYYKWK (SEQ ID NO:10).